Companies / Poland
Bioton Turns Sights On Russia
September 2006 | Company News AlertDemonstrating commitment to expanding beyond its saturated domestic market, Polish biotechnology firm Bioton is planning to capture a sizeable share of the Russian insulin market following the approval of three of its recombinant human insulin products there. Additionally, the company has longer term plans to penetrate the Ukraine, Asia, Western Europe and even the US, eventually gaining 10% of the global market for
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
